← Issue №9/ week of Aug 30, 2026/Hepatology

Meta-Analysis: Enhanced Liver Fibrosis (ELF) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

From GI Signals issue №9: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology meta analysis · n=3,700 · Aug 24, 2026 · Aliment Pharm Ther · IF 6.7

Meta-Analysis: Enhanced Liver Fibrosis (ELF) Test for Identifying Significant Fibrosis, Advanced Fibrosis, and Cirrhosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

New evidencebiomarkermeta-analysisMASLDcirrhosis
Clinical takeawayUse ELF <9.00 to rule out ≥F2 fibrosis in MASLD (caution: 14% Spec). Consider ELF ≥9.80 for ≥F3 and ≥11.30 for F4. ELF ≥10.50 may inform anti-fibrotic therapy decisions but requires validation.
What it foundELF test cutoffs for MASLD fibrosis: Youden cutoffs: ≥F2 (9.37, AUROC 0.818), ≥F3 (9.64, AUROC 0.818), F4 (9.99, AUROC 0.774). Guideline-recommended cutoffs: ≥F2 (9.00: 86% Sens, 61% Spec), ≥F3 (9.80: 70% Sens, 79% Spec), F4 (11.30: 21% Sens, 96% Spec; 10.50: 50% Sens, 86% Spec). Rule-out ≥F2 at ELF <9.00 (98% Sens, 14% Spec); ELF 7.70 is non-meaningful.
ContextMeta-analysis comparing Youden vs. guideline-recommended ELF cutoffs for MASLD fibrosis staging. Highlights tradeoffs in sensitivity/specificity.
Emergingsuggested applicable standard· AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674.

Decision at stakethe use of non-invasive tests to assess liver fibrosis in MASLD

Statins are safe and recommended in MASLD/MASH and compensated cirrhosis when indicated for cardiovascular risk reduction. Start per standard CV risk-based criteria with baseline LFTs; routine ALT monitoring on statin is not required and pre-existing transaminitis is not a contraindication. Hold or reduce only for clinically significant ALT elevation, severe muscle symptoms, or decompensated cirrhosis on an individualized basis.

AASLD, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease" (Rinella ME et al., Hepatology 2023;77(5):1797-1835). DOI 10.1097/HEP.0000000000000323, PMID 36727674. · reviewed 2026-07-21 ↗
Gee MFW … Sanyal AJ · Alimentary Pharmacology & Therapeutics · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №9 Every paper GI Signals surfaces gets a page like this one. All issues